Toggle Side Panel
Close search

Cefazolin better than flucloxacillin for MSSA, Aussie research finds

The research also found that benzylpenicillin is a better option than flucloxacillin or cloxacillin for penicillin-susceptible Staphylococcus aureus infections.

A commonly used antibiotic for Staphylococcus aureus bacteraemia is not the safest choice, an Australian-led global trial has concluded. 

Researchers say cefazolin should be the first option for methicillin-susceptible S. aureus (MSSA), ahead of flucloxacillin, whereas Therapeutic Guidelines currently lists the two as equal first-line treatments. 

They have also shown that benzylpenicillin is a better option than flucloxacillin or cloxacillin for penicillin-susceptible S. aureus (PSSA) infections — something the guideline supports already for confirmed cases. 

Results from their 14-country S. aureus Network Adaptive Platform Trial (SNAP Trial) were published in The New England Journal of Medicine and The Lancet this week. 

Report

Harassment or bullying behavior
Contains mature or sensitive content
Contains misleading or false information
Contains abusive or derogatory content
Content that breaches the privacy of other individuals
Contains spam, fake content or potential malware

Block Member?

Please confirm you want to block this member.

You will no longer be able to:

  • See blocked member's posts
  • Mention this member in posts
  • Message this member
  • Add this member as a connection

Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.

Report

You have already reported this .